Autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis

Annals of the Academy of Medicine Singapore

Volumn 36, Issue 6, 2007, Pages 421-426

  Loh, Yvonne S M ^a   Hwang, William Y K ^a   Ratnagopal, Pavanni ^b  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

Author keywords

Autoimmunity; Induction of tolerance; Progressive multiple sclerosis

Indexed keywords

ARABINOSIDE; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; STEROID; THYMOCYTE ANTIBODY;

ASIA; AUTOIMMUNE DISEASE; AUTOIMMUNITY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW TOXICITY; DISEASE SEVERITY; HUMAN; MEDLINE; MULTIPLE SCLEROSIS; NEUTROPENIA; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; REVIEW; SAFETY; SINGAPORE; STANDARD;

EID: 34547816714     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Confavreux C, Ainard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980;103:281-300.
2. Cottrell DA, Kremenchutzky M, Rica GP, Koopman WJ, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 1999;122:625-39.
3. Kremenchutzky M, Cottrell D, Rice G, Hader W, Baskerville J, Koopman W, et al. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a reevaluation. Brain 1999;122:1941-50.
4. Confavreux C, Vukusic S, Moreau T, Adeline P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343:1430-8.
5. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343:938-52.
6. Grossman Z, Singer A. Tuning of activation thresholds explains flexibility in the selection and development of T cells in the thymus. Proc Natl Acad Sci U S A 1996;93:14747-52.
7. Grossman Z, Paul WE. Adaptive cellular interactions in the immune system: the tunable activation threshold and the significance of subthreshold responses. Proc Natl Acad Sci U S A 1992;89:10365-9.
8. Davidson A, Diamond B. Autoimmune diseases. N Engl J Med 2001;345:340-50.
9. Guillaume T, Rubinstein DB, Symann M. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood 1998;92:1471-90.
10. van Bekkum DW. Stem cell transplantation for autoimmune disorders. Preclinical experiments. Best Pract Res Clin Haematol 2004;17:201-22.
11. Singer DE, Moore MJ, Williams RM. EAE in rat bone marrow chimeras: analysis of the cellular mechanism of BN resistance. J Immunol 1981;126:1553-7.
12. Van Gelder M, von Bekkum DW. Treatment of relapsing experimental autoimmune encephalomyelitis in rats with allogeneic bone marrow transplantation from a resistant strain. Bone Marrow Transplant 1995;16:343-51.
13. Van Gelder M, Mulder AH, van Bekkum DW. Treatment of relapsing experimental autoimmune encephalomyelitis with largely MHC-matched allogeneic bone marrow transplantation. Transplantation 1996:62:810-8.
14. van Gelder M, Kinwel-Bohre EPM, van Bekkum DW. Treatment of experimental autoimmune encephalomyelitis in rats with total body irradiation and syngeneic bone marrow transplantation. Bone Marrow Transplant 1993:11:223-41.
15. van Gelder M, van Bekkum DW. Effective treatment of relapsing experimental autoimmune encephalomyelitis with pseudoautologous bone marrow transplantation. Bone Marrow Transplant 1996:18:1029-34.
16. Mandalfino P, Rice G, Smith A, Klein JL, Ryestedt L, Ebers GC. Bone marrow transplantation in multiple sclerosis. J Neurol 2000;247:691-5.
17. Meloni G, Capria S, Salvetti M, Cordone I, Mancini M, Mandelli F. Autologous peripheral blood stem cell transplantation in a patient with multiple sclerosis and concomitant Ph+ acute leukemia. Haematologica 1999;84:665-7.
18. Jeffrey ER, Alshami E. Allogeneic bone marrow transplant in multiple sclerosis (abstract). Neurology 1998;50:A147.
19. Fassas A, Anagnostopoulos A, Kazis A, Kapinas K, Sakellari I, Kimiskidis V, et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant 1997;20:631-8.
20. Burt RK, Traynor AE, Cohen B, Karin KH, Davis FA, Stefoski D, et al. T-cell depleted autologous haematopoietic stem cell transplantation for multiple sclerosis: report on the first three patients. Bone Marrow Transplant 1998;21:537-41.
21. Burt RK, Cohen BA, Lobeck LJ, Oyama Y, Traynor A, Burns WH. Immune suppressive therapy with autologous hematopoietic stem cell transplantation arrests active CNS inflammation but not axonal atrophy in patients with severe disability and progressive multiple sclerosis (abstract). Blood 2001;98:687a.
22. Burt RK, Traynor AE, Pope R, Schroeder J, Cohen B, Karlin KH, et al. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood 1998;92:3505-14.
23. Carreras E, Saiz A, Graus F, Marin P, Martinez C, Rovira M, et al. Autologous CD34 selected haematopoietic stem cell transplantation for multiple sclerosis: update of a single center experience in 10 patients (abstract). Biol Blood Marrow Transplant 2001;7:69.
24. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
25. Saiz A, Carreras E, Berenguer J, Yague J, Martinez C, Marin P, et al. MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS. Neurology 2001;56:1084-9.
26. Nash RA, Bowen JD, McSweeney PA, Pavletic SZ, Maravilla KR, Park MS, et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 2003;102:2364-72.
27. Burt RK, Cohen BA, Russell E, Spero K, Joshi A, Oyama Y, et al. Haematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood 2003;102:2373-8.
28. Fassas A, Passweg JR, Anagnostopoulos A, Kazis A, Kozak T, Havrodova E, et al; Autoimmune Disease Working Party of the EBMT (European Group for Blood and Marrow Transplantation). Hematopoietic stem cell transplantation for multiple sclerosis: A retrospective multicenter study. J Neurol 2002;249:1088-97. Erratum in: J Neurol 2002;249:1619.
29. Fassas A, Kimiskidis VK. Autologous hemopoietic stem cell transplantation in the treatment of multiple sclerosis: rationale and clinical experience. J Neurol Sci 2004;223:53-8.
30. Mancardi GL, Saccardi R, Filippi M, Gualandi F, Murialdo A, Inglese M, et al; Italian GITMO-NEURO Intergroup on Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. Neurology 2001;57:62-8.
31. Fassas A, Anagnostopoulos A, Kazis A, Kapinas K, Sakellari I, Kimiskidis V, et al. Autologous stem cell transplantation in progressive multiple sclerosis - an interim analysis of efficacy. J Clin Immunol 2000;20:24-30.
32. Comi G, Kappos L, Clanet M, Ebers G, Fassas A, Fazekas F, et al; BMT-MS Study Group. Guidelines for autologous blood and marrow transplantation in multiple sclerosis: a consensus report written on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot Foundation. J Neurol 2000;247:376-82.
33. Barkhof F, Filippi M, Miller DH, Scheltens, P, Campi A, Polman CH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120:2059-69.
34. Loh SM, Ratnagopal P, Tan HC, Goh YT, Koh BC, Koh LP, et al. Successful autologous haematopoietic stem cell transplants for severe multiple sclerosis with fludarabine and cyclophosphamide conditioning [letter]. Int J Hematol 2006;83:368-9.
35. Openshaw H, Stuve O, Antel JP, Nash R, Lund BT, Weiner LP, et al. Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor. Neurology 2000;54:2147-50.
36. Burt RK, Fassas A, Snowden J, van Laar JM, Kozak T, Wulffraat NM, et al. Collection of hematopoietic stem cells from patients with autoimmune diseases. Bone Marrow Transplant 2001;28:1-12.
37. Euler HH, Marmont AM, Bacigalupo A, Fastenrath S, Dreger P, Hoffknecht M, et al. Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation. Blood 1996;88:3621-5.
38. Bomberger C, Singh-Jairam M, Rodney G, Guerriero A, Yeager AM, Fleming WH, et al. Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors. Blood 1998;91:2588-600.
39. Sica S, Salutari P, La Barbera EO, Sora F, Piccirillo N, Leone G. Infectious complications after CD-34 selected autologous peripheral blood stem cell transplantation. Br J Haematol 1998;101:592-3.
40. van Bekkum DW. Stem cell transplantation in experimental models of autoimmune diseases. J Rheumatol 1997;48(suppl):30-5.
41. Moore J, Brooks P, Milliken S, Biggs J, Ma D, Handel M, at al. A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis. Arthritis Rheum 2002;46:2301-9.
42. Omaya Y, Cohen B, Traynor A, Brush M, Rodriguez J, Burt RK. Engraftment syndrome: a common cause for rash and fever following autologous hematopoietic stem cell transplantation for multiple sclerosis. Bone Marrow Transplant 2002;29:81-5.
43. Murphy CB, Hashimoto SA, Graeb D, Thiessen BA. Clinical exacerbation of multiple sclerosis following radiotherapy. Arch Neurol 2003;60:273-5.
44. Kozak T, Hardova E, Pit'ha J, Gregora E, Pytlik R, Maaloufova J, et al. High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis. Bone Marrow Transplant 2000;25:525-31.
45. Blanco Y, Saiz A, Carreras E, Graus F. Autologous haematopoietic-stem- cell transplantation for multiple sclerosis. Lancet Neurol 2005;4:54-63.
46. Burt RK, Slavin S, Burns WH, Marmont AM. Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure? Blood 2002;99:768-84.
47. Loberiza FR Jr, Zhang MJ, Lee SJ, Klein JP, LeMaistre CF, Serna DS, et al. Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States. Blood 2005;105:2979-87.
48. Tyndall A, Gratwohl A. Blood and marrow stem cell transplants in autoimmune disease: a consensus report written on behalf of the European League against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1997;19:643-5.
49. Griffith LM, Pavletic SZ, Tyndall A, Bredeson CN, Bowen JD, Childs RW, et al. Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005. Biol Blood Marrow Transplant 2005;11:862-70.